# Adequan Polysulfated Glycosaminoglycan: Joint Injection Protocol ## Key Takeaways - Polysulfated glycosaminoglycan (PSGAG) is a disease-modifying osteoarthritis drug (DMOAD) that targets cartilage degradation by inhibiting matrix-degrading enzymes and stimulating chondrocyte production of collagen and glycosaminoglycans. - Intra-articular (IA) administration of PSGAG delivers high local concentrations to a single joint but carries a significant risk of potentiating septic arthritis, as demonstrated by experimental studies showing increased infectivity of bacteria. - The standard equine IA protocol involves 250 mg of PSGAG per joint, administered weekly for up to five treatments, while canine IA protocols are off-label and typically extrapolate from equine models with lower doses. - Intramuscular (IM) administration is the preferred and safer route for systemic treatment of multiple joints or chronic management, with established protocols for horses (500 mg every 4-7 days) and dogs (2 mg/lb twice weekly for up to 4 weeks). - PSGAG possesses heparin-like properties and can prolong bleeding times, necessitating caution in animals with clotting disorders or those undergoing surgery; rare but serious adverse events like thrombocytopenia have been reported in dogs. - Concurrent administration of an aminoglycoside antibiotic, such as amikacin, with IA PSGAG is a clinical strategy to mitigate the risk of iatrogenic infection, though this is an off-label use requiring veterinary discretion. --- **Owner Triage Summary:** Adequan (polysulfated glycosaminoglycan, PSGAG) is a disease-modifying osteoarthritis drug (DMOAD) used in horses and dogs. It can be given intramuscularly (IM) or directly into a joint (intra-articular, IA) by a veterinarian. The IA route delivers the drug directly to the inflamed joint but carries a higher risk of introducing infection. The standard IA protocol in horses is 250 mg once weekly for up to five treatments. The standard IM protocol in dogs is 2 mg/lb (4.4 mg/kg) twice weekly for up to four weeks. Never attempt to inject a joint at home. If your pet shows severe lameness, joint swelling, fever, or reluctance to bear weight after any injection, contact your veterinarian immediately. ## Understanding Polysulfated Glycosaminoglycan (PSGAG) Polysulfated glycosaminoglycan is a semi-synthetic, heparin-like molecule derived from bovine tracheal cartilage. It is classified as a slow-acting, disease-modifying osteoarthritis drug because it targets the underlying biochemical processes of cartilage degradation, rather than just masking pain [1]. It is widely used in equine and canine practice, with surveys indicating that over 90% of equine practitioners have used it [2]. The drug works through several mechanisms. It inhibits enzymes that break down cartilage matrix, such as metalloproteinases and aggrecanases. It also stimulates chondrocytes (cartilage cells) to produce new collagen and glycosaminoglycans, the building blocks of healthy cartilage [3]. Additionally, PSGAG has anti-inflammatory properties and improves synovial fluid quality [1]. Pharmacological studies show that PSGAG rapidly distributes to diseased joint tissue after either intra-articular or intramuscular administration. This means that systemic (IM) injection can still deliver therapeutic concentrations to the joints, especially those with active inflammation [1]. This is a key concept for clinicians: the IM route is often preferred for multiple joint involvement or as a prophylactic measure, while the IA route is reserved for targeted treatment of a single, severely affected joint. ## The Joint Injection Protocol: Intra-Articular (IA) Administration The intra-articular injection of PSGAG is a specific procedure that requires strict aseptic technique and should only be performed by a licensed veterinarian. The goal is to deliver a high concentration of the drug directly into the synovial space. ### Indications for IA PSGAG IA PSGAG is typically considered for: - Moderate to severe osteoarthritis in a single joint. - Joints that have not responded adequately to systemic therapy. - Acute synovitis or capsulitis. - As an adjunct to other IA therapies (though compatibility should be carefully evaluated). ### Standard Equine IA Protocol Based on the source literature, the most commonly studied and cited IA protocol in horses is: - **Dose:** 250 mg of PSGAG per joint. - **Frequency:** Once weekly. - **Duration:** Up to 5 treatments [4][5]. This protocol has been used in experimental models to evaluate both the chondroprotective effects and the potential complications of IA administration [4][5]. In one study, horses with induced cartilage injuries received 250 mg of PSGAG IA once a week for five weeks, starting one week after injury. The treatment resulted in less joint swelling and better cartilage preservation compared to controls [4]. Another study used the same protocol (250 mg weekly for 4 weeks, starting at surgery) to evaluate the effects on joints with osteochondral defects [5]. ### Standard Canine IA Protocol While PSGAG is FDA-approved for intramuscular use in dogs, IA injection is performed off-label. There is no single standardized IA protocol for dogs in the provided sources. The IM label dose is 2 mg/lb (4.4 mg/kg) twice weekly for up to four weeks [6]. When using IA in dogs, clinicians often extrapolate from the equine model, using a lower dose (e.g., 50-100 mg per joint) depending on the size of the joint and the patient. This is a decision that must be made on a case-by-case basis by the attending veterinarian. ### The IA Injection Procedure The procedure itself is critical. It involves: 1. **Clipping and Surgical Prep:** The hair over the joint is clipped and the skin is aseptically prepared with a surgical scrub (e.g., chlorhexidine or povidone-iodine). 2. **Sterile Technique:** The veterinarian wears sterile gloves. The injection site is palpated, and a sterile needle is inserted into the joint space. 3. **Synoviocentesis:** Before injecting, the veterinarian may aspirate synovial fluid to confirm needle placement and to relieve pressure. 4. **Injection:** The PSGAG is injected slowly and smoothly. 5. **Bandaging:** A sterile pressure bandage may be applied to the joint for 24-48 hours to minimize swelling. ### The Critical Risk: Infection Potentiation The most significant risk associated with IA PSGAG is the potentiation of septic arthritis. This is not a theoretical risk; it is a well-documented experimental finding. Research by Gustafson et al. demonstrated that PSGAG significantly increases the infectivity of *Staphylococcus aureus* in equine joints [7][8]. In one landmark study, a subinfective dose of *S. aureus* (33 colony-forming units) was injected into the joints of horses. When this dose was combined with 250 mg of PSGAG, all 8 horses developed severe septic arthritis. In contrast, only 1 of 8 control horses (given saline) developed infection [7][8]. This effect was not mitigated by filtering the PSGAG [7]. This potentiation is thought to be due to the immunosuppressive effects of PSGAG on local synovial defenses. It is a critical reminder that IA injection of PSGAG is not a benign procedure. The risk of introducing bacteria into a joint is always present, and PSGAG appears to lower the threshold for infection. **Mitigation Strategy:** The same study found that adding 125 mg of amikacin to the injectate immediately after inoculation significantly decreased the potentiation of infection [7]. This has led to a common clinical practice of co-administering a small dose of an aminoglycoside antibiotic (like amikacin) with IA PSGAG to reduce the risk of iatrogenic infection. This is a decision for the veterinarian, weighing the benefits against the potential for antibiotic-induced cartilage damage. ## The Intramuscular (IM) Protocol: A Systemic Approach The intramuscular route is the most common and safest method of PSGAG administration. It is FDA-approved for both horses and dogs. It is the preferred route for treating multiple joints, for chronic management, and for owners who are trained to administer injections at home. ### Equine IM Protocol The typical equine IM protocol is: - **Dose:** 500 mg (two 250 mg injections) per horse. - **Frequency:** Every 4-7 days. - **Duration:** 4 to 6 treatments, repeated as needed. This protocol has been shown to be effective in reducing the severity of joint injuries. Studies in Thoroughbred foals have evaluated the prophylactic use of IM PSGAG to attenuate the effects of developmental and traumatic joint injuries [9][10]. While the exact protocols vary, the goal is to provide systemic coverage to all joints. ### Canine IM Protocol The canine IM protocol is well-established and label-approved: - **Dose:** 2 mg/lb (4.4 mg/kg) of body weight. - **Frequency:** Twice weekly. - **Duration:** Up to 4 weeks (8 injections total). This can be repeated after a rest period. A 2025 randomized, controlled, blinded study confirmed the efficacy of this IM protocol in dogs with osteoarthritis. Dogs receiving the standard IM dose (2 mg/lb twice weekly for 4 weeks) showed significant improvement in pain scores, though the improvement took longer to manifest than in a group receiving aqua-acupuncture injections [6]. ### Subcutaneous (SC) Administration in Dogs While the label specifies IM, PSGAG is commonly administered subcutaneously (SC) by owners at home. A 2021 survey of 69 dogs found that SC administration is generally well-tolerated. Most adverse events were minor (stomach upset, loose stool, injection site pain, fear) and did not lead to discontinuation of therapy. However, one [dog](/knowledge/veterinary-medicine/clinical-methods/dog) experienced a severe adverse event (thrombocytopenia, bruising) that resolved after stopping the drug [11]. This highlights that while SC is convenient, it is an off-label route, and owners should be educated on the signs of adverse reactions. ## Comparative Efficacy: IA vs. IM The choice between IA and IM PSGAG is a clinical decision. Both routes have evidence supporting their use. | Feature | Intra-Articular (IA) | Intramuscular (IM) | | :--- | :--- | :--- | | **Target** | Single, specific joint | Systemic (all joints) | | **Drug Concentration** | Very high in the target joint | Lower, but distributed to diseased joints [1] | | **Procedure** | Invasive, requires sedation and strict aseptic prep | Minimally invasive, can be done in a standing or awake patient | | **Risk of Infection** | **High** (PSGAG potentiates infection) [7][8] | Very Low | | **Typical Equine Dose** | 250 mg/joint, weekly x 5 [4] | 500 mg/horse, every 4-7 days | | **Typical Canine Dose** | Off-label, clinician discretion | 2 mg/lb (4.4 mg/kg), twice weekly x 4 weeks [6] | | **Onset of Action** | Potentially faster in the target joint | Slower, but more uniform | | **Best Use Case** | Severe single-joint OA, acute flare-up | Multiple joint OA, prophylactic use, long-term management | **Clinical Perspective:** Many practitioners prefer IM PSGAG as the first-line DMOAD therapy. It is safer and addresses the systemic nature of osteoarthritis, which often affects multiple joints. IA PSGAG is reserved for cases where a single joint is the primary source of lameness and has not responded to systemic therapy. The decision should always be made after a full diagnostic workup, including radiographs and possibly synovial fluid analysis. ## Evidence for Chondroprotection and Clinical Efficacy The classification of PSGAG as a DMOAD is supported by a substantial body of laboratory and clinical research [1]. ### In Vitro and Explant Studies The effects of PSGAG on cartilage are complex and dose-dependent. - **Stimulation of Matrix Synthesis:** One study found that low molecular weight PSGAG stimulated net collagen and glycosaminoglycan synthesis by arthritic equine cartilage tissues, with arthritic tissues being more sensitive to the drug [3]. - **Inhibition of Degradation:** The same study found that concentrations of PSGAG similar to those found in synovial fluid after IA injection inhibited the rate of collagen and glycosaminoglycan degradation [3]. - **Conflicting Results:** However, other explant studies have shown a dose-dependent depression of proteoglycan synthesis in normal cartilage [12][13]. This suggests that PSGAG may have different effects on normal versus arthritic cartilage, and that high concentrations may be detrimental to healthy tissue. This reinforces the need for careful dosing and route selection. ### In Vivo Studies - **Equine Cartilage Repair:** In a study using a chemical model of arthritis (monoiodoacetate injection), horses treated with IA PSGAG (250 mg weekly x 5) had less joint swelling, less cartilage fibrillation, and greater glycosaminoglycan staining compared to untreated controls. However, PSGAG did not improve healing of full-thickness physical defects [4]. - **Corticosteroid Mitigation:** PSGAG has been shown to mitigate some of the deleterious effects of intra-articular corticosteroids on cartilage. In a study with ponies, those receiving IM PSGAG alongside intra-articular methylprednisolone acetate had better cartilage parameters than those receiving the steroid alone [14]. - **Prophylactic Use:** Studies in Thoroughbred foals suggest that prophylactic IM PSGAG may help attenuate the effects of joint injuries, potentially reducing the severity of developmental orthopedic disease [9][10]. ### Clinical Surveys and Perceived Efficacy A large survey of equine practitioners found that PSGAG was considered "moderately effective" in treating various forms of degenerative joint disease. Lameness specialists used it more frequently than general practitioners, and it was most popular among those treating racing Thoroughbreds [2]. This real-world data confirms that PSGAG is a valuable tool, though it is not a cure-all. ## Risks, Side Effects, and Contraindications While PSGAG is generally safe, it is not without risks. ### Coagulation Effects PSGAG is a heparin-like molecule. It can prolong bleeding times. In one study, PSGAG was evaluated for its effects on activated partial thromboplastin time (aPTT), prothrombin time (PT), and other parameters in cats [15]. While the abstract is not fully detailed, the very existence of this study highlights the concern. It should be used with caution in animals with known clotting disorders or in those about to undergo surgery. ### Adverse Events in Dogs The 2021 owner survey on SC administration reported an overall adverse event rate of 18.8%. Most were minor, but one severe case of thrombocytopenia (low platelet count) and bruising was reported [11]. This is a rare but serious potential side effect. ### Potentiation of Sepsis (IA Route) As discussed, the IA route significantly potentiates the infectivity of bacteria [7][8]. This is the most serious risk and requires strict adherence to aseptic technique and consideration of concurrent antibiotic use. ### Contraindications - **Known hypersensitivity** to PSGAG. - **Bleeding disorders** or concurrent use of anticoagulants. - **Septic arthritis:** PSGAG should never be injected into an infected joint. - **Intra-articular use** in a joint with a compromised immune environment. ## Procedure and Handling: A Step-by-Step Guide for Veterinarians For the veterinary professional, the following steps outline a safe IA injection protocol. 1. **Patient Preparation:** Confirm the patient's health status. Review any history of bleeding disorders. For horses, mild sedation may be used. For dogs, sedation or general anesthesia is often required for safe IA injection. 2. **Aseptic Preparation:** Clip a wide area around the joint. Scrub the skin with chlorhexidine or povidone-iodine for a full 5 minutes. Use sterile gloves and a sterile field. 3. **Joint Entry:** Palpate the joint landmarks. Insert a sterile needle (e.g., 20-22 gauge for horses, 22-25 gauge for dogs) into the joint space. Confirm placement by aspirating synovial fluid. 4. **Injection:** Attach the syringe containing the PSGAG. Inject slowly. Some clinicians choose to mix the PSGAG with a small dose of amikacin (e.g., 125 mg for horses) to mitigate the risk of infection potentiation [7]. This is an off-label use and should be discussed with the owner. 5. **Post-Injection Care:** Apply a sterile pressure bandage. Restrict exercise for 24-48 hours. Monitor the joint for excessive swelling, heat, or pain, which could indicate a reaction or infection. ## Limitations and When to Contact a Veterinarian This article provides a detailed overview of PSGAG protocols, but it cannot replace a professional diagnosis. The information presented here is based on specific research studies and clinical surveys. It does not predict the outcome for any individual animal. Breed, age, the severity of arthritis, and the presence of other health conditions all influence the response to therapy. **Emergency Red Flags (Contact your vet immediately):** - Severe, sudden-onset lameness in the injected limb. - Marked swelling, heat, or redness around the joint. - Fever, lethargy, or loss of appetite. - Any sign of bleeding or bruising at the injection site or elsewhere. - Vomiting, diarrhea (or diarrhoea), or persistent gastrointestinal upset after systemic administration [11]. If you are considering PSGAG therapy for your pet, discuss the risks and benefits of both the IM and IA routes with your veterinarian. They can help you decide which protocol is most appropriate for your animal's specific condition. ## Frequently Asked Questions ### 1. Can I give my horse or dog an Adequan joint injection at home? No. Intra-articular injections must be performed by a veterinarian using strict sterile technique. The risk of introducing bacteria into the joint is too high, and PSGAG can potentiate a severe infection [7][8]. Attempting this at home can lead to life-threatening septic arthritis. ### 2. What is the difference between the intramuscular and intra-articular routes for Adequan? The intramuscular (IM) route delivers the drug systemically, affecting all joints, and is the safest and most common route. The intra-articular (IA) route delivers a high concentration of the drug directly into a single, specific joint. The IA route carries a significantly higher risk of infection and requires a veterinary procedure [7][1]. ### 3. How often is Adequan given for osteoarthritis in dogs? The FDA-approved label dose for dogs is 2 mg/lb (4.4 mg/kg) administered intramuscularly twice weekly for up to four weeks [6]. This is a common protocol for an initial course of therapy. ### 4. What is the standard Adequan injection protocol for a horse's joint? For intra-articular use, the most common protocol studied is 250 mg of PSGAG injected directly into the affected joint once weekly for up to five treatments [4][5]. For intramuscular use, a typical protocol is 500 mg every 4-7 days. ### 5. Is Adequan a steroid or a painkiller? No. Adequan (PSGAG) is a disease-modifying osteoarthritis drug (DMOAD). It works by inhibiting cartilage-destroying enzymes and stimulating cartilage repair, rather than simply masking pain or reducing inflammation like a steroid [1]. ### 6. What are the common side effects of Adequan injections? Side effects are generally mild. In dogs, they can include stomach upset, loose stool, pain at the injection site, and temporary fear [11]. A rare but severe side effect is thrombocytopenia (low blood platelets), which can cause bruising [11]. Because it has heparin-like properties, it can also affect blood clotting [15]. ### 7. Why is there a risk of infection with intra-articular Adequan? Research has shown that PSGAG can potentiate the infectivity of bacteria like *Staphylococcus aureus*. In experimental studies, a dose of bacteria that normally would not cause an infection did cause severe septic arthritis when combined with PSGAG [7][8]. This is why strict aseptic technique is mandatory. ### 8. Can Adequan be given subcutaneously (under the skin) to dogs? While the label specifies intramuscular use, many owners are taught to give it subcutaneously at home. A 2021 survey found this route is generally well-tolerated, with mostly minor side effects [11]. However, it is an off-label use, and you should discuss the risks and proper technique with your veterinarian. ## Related Clinical & Scientific Guides * [Drontal Plus Dewormer: Broad-Spectrum Dose Guide by Weight](/knowledge/veterinary-medicine/calculators-clinical-tools/drontal-plus-dewormer-broad-spectrum-dose-guide-by-weight) * [Panacur Fenbendazole Dewormer: Dog Fecal Parasite Treatment Schedule](/knowledge/veterinary-medicine/calculators-clinical-tools/panacur-fenbendazole-dewormer-dog-fecal-parasite-treatment-schedule) * [Prednisolone for Cats: Feline Safe Steroid Dose and Autoimmune](/knowledge/veterinary-medicine/calculators-clinical-tools/prednisolone-for-cats-feline-safe-steroid-dose-and-autoimmune)